Abstract
For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds
Volume: 21 Issue: 30
Author(s): Hayrettin O. Gulcan*Ilkay E. Orhan*
Affiliation:
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10,Turkey
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara,Turkey
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Abstract: For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Export Options
About this article
Cite this article as:
Gulcan O. Hayrettin *, Orhan E. Ilkay *, Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds, Current Topics in Medicinal Chemistry 2021; 21 (30) . https://dx.doi.org/10.2174/1568026621666210902121148
DOI https://dx.doi.org/10.2174/1568026621666210902121148 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Current Alzheimer Research Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation
Current Drug Targets Nociceptinergic System as Potential Target in Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Oral Supplements of <i>Ginkgo biloba</i> Extract Alleviate Neuroinflammation, Oxidative Impairments and Neurotoxicity in Rotenone-Induced Parkinsonian Rats
Current Pharmaceutical Biotechnology Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice
Central Nervous System Agents in Medicinal Chemistry Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease – A Focused Review
Current Gene Therapy TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies
Current Alzheimer Research Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued)